Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial

Gut

Volumn 46, Issue 4, 2000, Pages 562-568

  Schalm, S W ^a   Gray, D F ^g   Heathcote, J ^b   Cianciara, J ^c   Farrell, G ^d   Sherman, M ^b   Willems, B ^e   Dhillon, A ^f   Moorat, A ^g   Barber, J ^g  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d UNIVERSITY OF SYDNEY   (Australia)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Alpha interferon; Chronic hepatitis B; Combination therapy; HBeAg seroconversion; Hepatitis B virus; Lamivudine; Nucleoside analogue

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; LAMIVUDINE; RECOMBINANT ALPHA2B INTERFERON;

ADOLESCENT; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0034105307     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.46.4.562     Document Type: Article

References (21)

1. 1 Thomas HC. Pathogenesis of chronic HBV infection and mechanism of action of antiviral compounds. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore: Williams and Wilkins, 1991:612-15.
2. 2 Lok ASF, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992;102:2091-7.
3. 3 Perrillo RP, Schiff ER, Davis GL, et al. A randomised, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
4. 4 Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis Be antigen positive chronic hepatitis B. Ann Intern Med 1993;119:312-23.
5. 5 Krogsgaard K, Bindslev N, Christensen E, et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. J Hepatol 1994;21:646-55.
6. 6 Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989;10:761-3.
7. 7 Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis 1989;9:273-7.
8. 8 Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47.
9. 9 Severini A, Liu XY, Wilson JS, Tyrrell DL. Mechanism of inhibition of duck hepatitis B virus polymerase by 2′3′dideoxy 3′ thiacytidine. Antimicrob Agents Chemother 1995;39: 1430-5.
10. 10 Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
11. 11 Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomised dose-ranging study. Gastroenterology 1997;113:1258-63.
12. 12 Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339: 61-8.
13. 13 De Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators of hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-5.
14. 14 Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334: 1422-7.
15. 15 Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
16. 16 Shah BV, Barnwell BG, Bieler GS, et al. Statistical methods and algorithms used in Sudaan. Technical manual. Sudaan: Research Triangle Institute (GEE), 1996.
17. 17 Janssen HLA, Gerken G, Carreño V, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. Hepatology 1999;30:238-43.
18. 18 Schiff E, Cianciara J, Kowdley K, et al. Durability of HBeAg seroconversion after lamivudine monotherapy in controlled phase II and phase III trials. Hepatology 1998;28:163A.
19. 19 Brook MG, Petrovic L, McDonald JA, Scheuer PJ, Thomas HC. Histological improvement after anti-viral treatment for chronic hepatitis B virus infection. J Hepatol 1989;8:218-25.
20. 20 Honkoop P, Niesters HGM, Man RA de, Osterhaus ADME, Schalm SW. Lamivudine resistance in immuno-competent chronic hepatitis B: incidence and patterns. J Hepatol 1997;26:1393-5.
21. 21 Mutimer D, Naoumov N, Honkoop P, et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon resistant chronic hepatitis B infection: results of a pilot study. J Hepatol 1998;28:923-9.